Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin

被引：0
|
作者：
Lip, G. Y. H. [1 ]
Pan, X. [2 ]
Kamble, S. [2 ]
Kawabata, H. [2 ]
Mardekian, J. [3 ]
Masseria, C. [3 ]
Bruno, A. [2 ]
Phatak, H. [2 ]
机构：
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Bristol Myers Squibb Co, Princeton, NJ USA
[3] Pfizer Inc, New York, NY USA
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6217
引用
收藏
页码：1085 / 1085
页数：1
相关论文
共 50 条
  • [1] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [2] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986
  • [3] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763
  • [4] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [5] REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS
    Lip, Gregory
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 882 - 882
  • [6] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
    Amin, A.
    Keshishian, A.
    Trocio, J.
    Dina, O.
    Le, H.
    Rosenblatt, L.
    Mardekian, J.
    Zhang, Q.
    Baser, O.
    Liu, X.
    Vo, L.
    EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964
  • [7] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [8] Risk of Stroke and Major Bleeding for Dabigatran, Rivaroxaban, and Warfarin Compared to Apixaban Among Non-Valvular Atrial Fibrillation Patients in the United States Medicare Population
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Dina, Oluwaseyi
    Le, Hannah
    Rosenblatt, Lisa
    Liu, Xianchen
    Mardekian, Jack
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    CIRCULATION, 2017, 136
  • [9] Real-world comparisons of major bleeding risk and major bleeding-related hospitalization costs among elderly non-valvular atrial fibrillation patients newly initiated on apixaban or warfarin
    Kamble, S.
    Keshishian, A.
    Pan, X.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 496 - 496
  • [10] Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    Squibb, Bristol-Myers
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
12345